✦ LIBER ✦

Phase II trial of combined radiotherapy and daily low-dose cisplatin for inoperable, locally advanced non-small cell lung cancer (NSCLC)

✍ Scribed by Gerrit Van Harskamp; Epie Boven; Jan B. Vermorken; Henk Van Deutekom; Jaap Stam; K. Hian Njo; A.B.M.F. Karim; Anton H. Tierie; Richard P. Golding; Herbert M. Pinedo

Publisher: Elsevier Science
Year: 1987
Tongue: English
Weight: 527 KB
Volume: 13
Category: Article
ISSN: 0360-3016
DOI: 10.1016/0360-3016(87)90171-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radiotherapy and cis-diammine dichloropl

Radiotherapy and cis-diammine dichloroplatinum (II) as a combined treatment modality for inoperable non-small cell lung cancer: A dose finding study

✍ Caro Schaake-Koning; Harry Bartelink; Bouke Hora Adema; Lon Schuster-Uitterhoeve 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 625 KB

Phase ii evaluation of a combination of

Phase ii evaluation of a combination of mitomycin C, vincristine, and cisplatin in advanced non-small cell lung cancer

✍ Alex Yuang-Chi Chang; J. Philip Kuebler; Douglass C. Tormey; Susan Anderson; Kis 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 606 KB

A phase I trial of ifosfamide, mesna, an

A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer a cancer and leukemia group B study

✍ Stephen L. Graziano; James E. Herndon II; Frederick Richards II; Santo Difino; C 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 737 KB

Phase II trial of a 75-mg/m2 dose of doc

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

✍ Vincent A. Miller; James R. Rigas; Prudence A. Francis; Stefan C. Grant; Katheri 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 493 KB 👁 2 views

## Background. A prior Phase I1 study of a 100-mg/m2 dose of docetaxel conducted at the Memorial Sloan-Kettering Cancer Center (New York, NY) demonstrated a 38% response rate with grade 3 or 4 neutropenia in 76% of the patients and a grade 2 or greater rash or infusionrelated reaction in 41% and 3

Platinum-based combination chemotherapy

Platinum-based combination chemotherapy in advanced non-small cell lung cancer: A randomized phase II trial of the cancer and leukemia group B

✍ Green, Mark R. ;Kramar, Andrew ;Schilsky, Richard ;Stoopler, Marc ;Zimmer, Bonni 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 504 KB

## Abstract The Cancer and Leukemia Group B (CALGB) utilized a randomized phase II trial design to evaluate two cisplatin‐based combinations, cisplatin‐cytarabine (ara‐C) and cisplatin‐vinblastine, in 151 patients with advanced non‐small cell lung cancer. Patients entered on study had not received

110 Phase II clinical trial of amifostin

110 Phase II clinical trial of amifostine (WR2721), cisplatin (C), vinblastine (V) (ACV) and thoracic radiation therapy (RT) for unresectable stage III non small cell lung cancer (NSCLC).

✍ S. Tannehill; M. Mehta; M. Larson; B. Storer; J. Schiller; T. Kinsella 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 94 KB